These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 35656777)

  • 1. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
    Shore ND; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Tombal B; Nordquist L; Cookson M; Verholen F; Jhaveri J; Srinivasan S; Smith MR
    Oncologist; 2024 Mar; 29(3):235-243. PubMed ID: 37812679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
    Lee A
    Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial.
    Fizazi K; Blue I; Nowak JT
    Future Oncol; 2021 May; 17(14):1699-1707. PubMed ID: 33554636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
    Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
    Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford ED; Kopyltsov E; Park CH; Alekseev B; Montesa-Pino Á; Ye D; Parnis F; Cruz F; Tammela TLJ; Suzuki H; Utriainen T; Fu C; Uemura M; Méndez-Vidal MJ; Maughan BL; Joensuu H; Thiele S; Li R; Kuss I; Tombal B;
    N Engl J Med; 2022 Mar; 386(12):1132-1142. PubMed ID: 35179323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
    Saad F; Hussain MHA; Tombal B; Fizazi K; Sternberg CN; Crawford ED; Nordquist LT; Bögemann M; Tutrone R; Shore ND; Belkoff L; Fralich T; Jhaveri J; Srinivasan S; Li R; Verholen F; Kuss I; Smith MR
    Eur Urol; 2024 Oct; 86(4):329-339. PubMed ID: 38644146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    Hussain M; Tombal B; Saad F; Fizazi K; Sternberg CN; Crawford ED; Shore N; Kopyltsov E; Kalebasty AR; Bögemann M; Ye D; Cruz F; Suzuki H; Kapur S; Srinivasan S; Verholen F; Kuss I; Joensuu H; Smith MR
    J Clin Oncol; 2023 Jul; 41(20):3595-3607. PubMed ID: 36795843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
    Oh C; O'Callaghan M
    BMC Urol; 2024 Jul; 24(1):135. PubMed ID: 38951868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.
    Morgans AK; Grossman JP; Paracha N; Ladino D; Tyas E; Rodriguez-Santamaria F; Shore N
    J Manag Care Spec Pharm; 2024 Sep; 30(9):991-1000. PubMed ID: 38807035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
    Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
    Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
    Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
    ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Kasparek J; Humke C; von Koskull S; Chun FKH; Banek S; Mandel P
    Urologie; 2024 Mar; 63(3):254-261. PubMed ID: 38127147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
    Wala J; Nguyen P; Pomerantz M
    J Clin Oncol; 2023 Jul; 41(20):3584-3590. PubMed ID: 37267579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.